Dr. Lal PathLabs Declares ₹6 Interim Dividend; Q1FY26 PAT Rises 24% YoY to ₹1,340 Mn

New Delhi, July 31, 2025 – Dr. Lal PathLabs Ltd (NSE: LALPATHLAB, BSE: 539524) delivered a strong performance for the quarter ended June 30, 2025 (Q1 FY26), posting a consolidated net profit of ₹1,340 million – a 24% year-on-year increase driven by steady revenue growth and operational efficiency. Total income rose to ₹6,979 million, with revenue from operations at ₹6,698 million – reflecting a healthy uptick from both the previous quarter and the same period last year.

The company declared an interim dividend of ₹6 per share for FY26, with August 6, 2025, set as the record date. Earnings per share stood at ₹15.88 (basic) and ₹15.85 (diluted), while comprehensive income reached ₹1,331 million. Though net profit declined 13.8% quarter-on-quarter due to higher tax outgo, the overall performance remains resilient, supported by continued demand for diagnostic services and strategic operational expansion.

Detailed Q1FY26 Consolidated Financial Highlights (₹ in million)

For the quarter ended June 2025 (Q1FY26), the company reported a 24.3% year-on-year (YoY) increase in net profit after tax (PAT), reaching ₹1,340 million compared to ₹1,078 million in Q1FY25. However, on a sequential basis, PAT declined 13.8% from ₹1,555 million in Q4FY25.

Revenue from operations rose to ₹6,698 million, up from ₹6,019 million in the same quarter last year and ₹6,026 million in the previous quarter.

Total income stood at ₹6,979 million, while total expenses amounted to ₹5,168 million. Profit before tax (PBT) increased to ₹1,811 million, reflecting improved operational performance.

The company reported a tax expense of ₹471 million for the quarter. Basic and diluted EPS came in at ₹15.88 and ₹15.85, respectively.

Total comprehensive income for the quarter was ₹1,331 million, slightly lower than ₹1,529 million in Q4FY25 but higher than ₹1,077 million in Q1FY25.

The paid-up equity share capital stood at ₹838 million with other equity reported at ₹20,891 million as of FY25.

Dividend Announcement

Dr. Lal PathLabs’ Board of Directors has declared an interim dividend of ₹6 per equity share (60% of the face value of ₹10) for FY26. The record date for eligibility is August 6, 2025, and the dividend will be credited or dispatched within 30 days from the date of declaration.

Stock Performance

As of July 31, 2025, at 2:55 PM IST, Dr. Lal PathLabs’ stock traded at ₹3,161.50, up ₹62.40 or 2.01%, after opening at ₹3,031.00 and hitting an intraday high of ₹3,175.00; the company’s market cap stood at ₹26,380 crore, with a P/E ratio of 54.14, dividend yield of 0.76%, and a quarterly dividend amount of ₹6.01.

Segment & Strategic Outlook

Dr. Lal PathLabs, operating as a single-segment entity in the healthcare diagnostics sector, delivered strong margin performance in Q1 FY26, driven by operational efficiencies and disciplined cost management. The company continued its expansion into Tier 3 and Tier 4 markets, supported by a wide network of 298 labs, 6,607 patient service centres, and 12,365 pick-up points.

Despite inflationary pressure on employee and logistics costs, the company leveraged tools like Microsoft Dynamics 365 and StarLIMS to improve productivity and turnaround times. Management maintained a long-term focus on scaling volumes through affordable, bundled diagnostic offerings, rather than aggressive price hikes.

Analysts project steady 10–11% annual growth, supported by geographic diversification and strong brand leadership in India’s organised diagnostics space.

About Dr. Lal PathLabs

Dr. Lal PathLabs Limited, listed on NSE and BSE, is one of India’s leading diagnostic service providers. It offers a broad range of tests and healthcare packages across pathology and preventive diagnostics. The company has a strong pan-India network with a growing footprint in South Asia.

The consistent dividend payout and YoY profit growth reinforce Dr. Lal PathLabs’ stability and value proposition in the healthcare diagnostics space.

REF:https://nsearchives.nseindia.com/corporate/LALPATHLAB_31072025133004_FINALoutcomeJuly312025.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations